产品订购信息：
英文名称  Anti-SNF5 

中文名称   转录调控激活蛋白SNF5抗体说明书 

别    名  Snr1; TYE4; BAF47; hSNF5; INI1 antibody Integrase interactor 1 protein; RDT; Sfh1p; SMARCB1; SNF5; SNF5L1; Snr1; Sucrose nonfermenting yeast homolog like 1; SWI/SNF complex component SNF5; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1; SWI10; Transcription factor TYE4; Transcription regulatory protein SNF5.

浓    度   1mg/1ml

规 格  0.1ml/100μg 0.2ml/200μg

抗体来源   Rabbit

克隆类型   polyclonal

交叉反应   Human, Mouse, Rat, Chicken, Cow, Horse, Rabbit 

产品类型   一抗  

研究领域     染色质和核信号 信号转导

蛋白分子量  predicted molecular weight: 44kDa

性    状   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human SNF5 

亚    型   IgG

纯化方法   affinity purified by Protein A

储 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

转录调控激活蛋白SNF5抗体说明书 产品应用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蜡切片需做抗原修复） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存条件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

产品介绍 SNF5 is involved in transcriptional activation. The SWI/SNF complex is required for the induced expression of a large number of genes. This complex alters chromatin structure to facilitate binding of gene-specific dedicated transcription factors. SNF5 also funtions as a tumor suppressor gene and is frequently mutated in malignant rhabdoid tumors. It is also involved in adipocyte differentiation.

Function : Core component of the BAF (hSWI/SNF) complex. This ATP-dependent chromatin-remodeling complex plays important roles in cell proliferation and differentiation, in cellular antiviral activities and inhibition of tumor formation. The BAF complex is able to create a stable, altered form of chromatin that constrains fewer negative supercoils than normal. This change in supercoiling would be due to the conversion of up to one-half of the nucleosomes on polynucleosomal arrays into asymmetric structures, termed altosomes, each composed of 2 histones octamers. Stimulates in vitro the remodeling activity of SMARCA4/BRG1/BAF190A. Involved in activation of CSF1 promoter. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a post-mitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to post-mitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity). Plays a key role in cell-cycle control and causes cell cycle arrest in G0/G1. Also involved in vitamin D-coupled transcription regulation via its association with the WINAC complex, a chromatin-remodeling complex recruited by vitamin D receptor (VDR), which is required for the ligand-bound VDR-mediated transrepression of the CYP27B1 gene.

Subunit : Component of the BAF (hSWI/SNF) complex, which includes at least actin (ACTB), ARID1A, ARID1B/BAF250, SMARCA2, SMARCA4/BRG1/BAF190A, ACTL6A/BAF53, ACTL6B/BAF53B, SMARCE1/BAF57 SMARCC1/BAF155, SMARCC2/BAF170, SMARCB1/SNF5/INI1, and one or more of SMARCD1/BAF60A, SMARCD2/BAF60B, or SMARCD3/BAF60C. In muscle cells, the BAF complex also contains DPF3. Component of the WINAC complex, at least composed of SMARCA2, SMARCA4, SMARCB1, SMARCC1, SMARCC2, SMARCD1, SMARCE1, ACTL6A, BAZ1B/WSTF, ARID1A, SUPT16H, CHAF1A and TOP2B. Binds to double-stranded DNA. Interacts with MYK and MAEL. Interacts with PPP1R15A. Binds tightly to the human immunodeficiency virus-type 1 (HIV-1) integrase in vitro and stimulates its DNA-joining activity. Interacts with human papillomavirus 18 E1 protein to stimulate its viral replication. Interacts with Epstein-Barr virus protein EBNA-2. Component of neural progenitors-specific chromatin remodeling complex (npBAF complex) composed of at least, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, PHF10/BAF45A, ACTL6A/BAF53A and actin. Component of neuron-specific chromatin remodeling complex (nBAF complex) composed of at least, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, DPF1/BAF45B, DPF3/BAF45C, ACTL6B/BAF53B and actin (By similarity).

Subcellular Location : Nucleus.

Post-translational modifications : Phosphorylated upon DNA damage, probably by ATM or ATR.

DISEASE : Defects in SMARCB1 are a cause of schwannomatosis (SCHWA) [MIM:162091]; also called congenital cutaneous neurilemmomatosis. Schwannomas are benign tumors of the peripheral nerve sheath that usually occur singly in otherwise normal individuals. Multiple schwannomas in the same individual suggest an underlying tumor-predisposition syndrome. The most common such syndrome is NF2. The hallmark of NF2 is the development of bilateral vestibular-nerve schwannomas; but two-thirds or more of all NF2-affected individuals develop schwannomas in other locations, and dermal schwannomas may precede vestibular tumors in NF2-affected children. There have been several reports of individuals with multiple schwannomas who do not show evidence of vestibular schwannoma. Clinical report suggests that schwannomatosis is a clinical entity distinct from other forms of neurofibromatosis.

Similarity : Belongs to the SNF5 family.

转运蛋白SEC61B 多克隆抗体  SC61B Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

内质网蛋白SC65 多克隆抗体  SC65 Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

溶质载体家族6成员3 多克隆抗体  SC6A3 Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

溶质载体家族6成员4 多克隆抗体  SC6A4 Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

溶质载体家族6成员7 多克隆抗体  SC6A7 Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

磷酸化ADP核糖基化因子结合蛋白2抗体     转录因子NAC1抗体

锚蛋白重复及SAM结构域蛋白3抗体     转录因子MYB相关蛋白B抗体

磷酸化有丝分裂激酶B/C抗体     转录因子LMCD1抗体

磷酸化腺泡Acinus蛋白抗体     转录因子LHX6抗体

APS抗体     转录因子LBX1抗体

转铁蛋白 单克隆抗体  Transferrin Monoclonal Antibody  700/30ul#1540/100ul#2520/200ul

转铁蛋白 单克隆抗体  Transferrin Monoclonal Antibody  700/30ul#1540/100ul#2520/200ul

转铁蛋白 单克隆抗体  Transferrin Monoclonal Antibody  700/30ul#1540/100ul#2520/200ul

转铁蛋白 单克隆抗体  Transferrin Monoclonal Antibody  700/30ul#1540/100ul#2520/200ul

 单克隆抗体  Digoxin Monoclonal Antibody  700/30ul#1540/100ul#2520/200ul

冬凌草 Rabdosia rubescens(Hemsl.)Hara Ponicidin 冬凌草乙素 52617-37-5 C20H26O6 ≥98%

异啊魏醋IsofqrulicccidHPLC≥97%，20mg/支

柯伊利素-7-O-葡萄糖苷 Chrysoeriol 7-O-glucoside 19993-32-9 20mg HPLC≥98% 柯伊利素-7-O-葡萄糖苷 19993-...

中药对照药材宽筋藤121391-200401TLC法鉴别

Escin IIA;Aescin IIA七叶皂苷C纯度

转录调控激活蛋白SNF5抗体说明书豆科植物甘草 Glycyrrhiza uralensis Fisch. Neoisoliquiritin 新异甘草苷 7014-39-3 C21H22O9 ≥98%

泽泻醇BclisolB18649-93-910mg

黄芩Scellaria baicalesis 2',5,6',7-Teaxy7noxyflavanone none 80604-16-6 C15H12O6 单元素西溶液成分分析标准物质080594

中药对照药材番石榴叶121212-0101TLC法鉴别

Dephnoretin西瑞香素 纯度：≥98%

抗体的生物素化标记实验要点：

1. 转录调控激活蛋白SNF5抗体说明书 如在反应混合液中有叠氮钠或游离氨基存在,会抑制标记反应。因此,蛋白质在反应前要对 0.1mol/L碳酸氢钠缓冲液或0.5mol/L硼酸缓冲液充分透析；

2.所用的NHSB及待生物素化蛋白质之间的分子比按蛋白质表面的ε-氨基的密度会有所不同,选择不当则影响标记的效率,应先用几个不同的分子比来筛选最适条件；

3.用NHSB量过量也是不利的,抗原的结合位点可能因此被封闭,导致抗体失活；

4.由于抗体的氨基不易接近可能造成生物素化不足,此时可加入去污剂如 Triton x-100, Tween20等；

5.当游离ε-氨基(赖氨酸残基的氨基)存在于抗体的抗原结合位点时,或位于酶的催化位点时,生物素化会降低或损伤抗体蛋白的结合力或活性；

6.生物素还可能与不同的功能基团,如羰基、氨基、巯基、异咪唑基及苯酚基,也可与糖基共价结合；

7.交联反应后,应充分透析,否则,残余的生物素会对生物素化抗体与亲和素的结合产生竞争作用；

8.在细胞的荧光标记实验中,中和亲和素的本底低,但由于链霉亲和素含有少量正电荷,故对某些细胞可导致高本底。

抗体的鉴定：

1）转录调控激活蛋白SNF5抗体说明书 抗体的效价鉴定：不管是用于诊断还是用于,制备抗体的目的都是要求较高效价。不同的抗原制备的抗体,要求的效价不一。鉴定效价的方法很多,包括有试管凝集反应,琼脂扩散试验,酶联免疫吸附试验等。常用的抗原所制备的抗体一般都有约成的鉴定效价的方法,以资比较。如制备抗抗体的效价,一般就采用琼脂扩散试验来鉴定。

2）抗体的特异性鉴定：抗体的特异性是指与相应抗原或近似抗原物质的识别能力。抗体的特异性高,它的识别能力就强。衡量特异性通常以交叉反应率来表示。交叉反应率可用竞争抑制试验测定。以不同浓度抗原和近似抗原分别做竞争抑制曲线,计算各自的结合率,求出各自在IC50时的浓度,并按公式计算交叉反应率。 

如果所用抗原浓度IC50浓度为pg/管,而一些近似抗原物质的IC50浓度几乎是无穷大时,表示这一抗血清与其他抗原物质的交叉反应率近似为0,即该血清的特异性较好。

3）抗体亲和力：是指抗体和抗原结合的牢固程度。亲和力的高低是由抗原分子的大小,抗体分子的结合位点与抗原决定簇之间立体构型的合适度决定的。有助于维持抗原抗体复合物稳定的分子间力有氢键,疏水键,侧链相反电荷基因的库仑力,范德华力和空间斥力。亲和力常以亲和常数K表示,K的单位是L/mol。抗体亲和力的测定对抗体的筛选,确定抗体的用途,验证抗体的均一性等均有重要意义。